An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and effectively lower cholesterol levels.

BMY and VERV are in the spotlight this week following the failure of a late-stage study and positive cholesterol study data, respectively.

A phase 1b showed promising results in lowering LDL in patients with heterozygous familial hypercholesterolemia and/or ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Click here to find out why I rate VERV ...

Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.

After VERVE-102 showed the ability to lower LDL-C and PCSK9 in the Heart-2 trial, the firm said it will advance the therapy to a Phase II study later this year.

Verve Therapeutics, Inc.’s VERV share price has surged by 36.18%, which has investors questioning if this is right time to sell.

Positive early stage data for Verve Therapeutics Inc.’s base editing therapy points to a range of development options, ...

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

The results show dose-dependent LDL-lowering and, in contrast to what was seen previously with VERVE-101, no safety issues.

A Verve Therapeutics treatment was found to cut cholesterol levels by more than half—with just one shot. The stock jumped ...